Ranitidine

Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA₂ values of 7.2 and 6.95, respectively. Ranitidine inhibits breast tumor development and spread in mice^[1][2]. In Vivo:Ranitidine (0.03-3 mg/kg; i.v.; once) inhibits Histamine (HY-B1204)- and Pentagastrin (HY-A0261)-induced gastric acid secretion in the perfused stomach preparation of the anaesthetized rat^[1].
Ranitidine (8 mg/kg; oral administration; administered every other day; treatment for 8 days) reduces the number of CD11b⁺Ly6C^hi cells in the spleen and bone marrow of BALB/c mice^[2].
Ranitidine (8 mg/kg; oral administration; administered every other day; treatment for 8 days) inhibits lung metastasis in BALB/c mice bearing 4T1 breast cancer^[2].
Ranitidine (8 mg/kg; oral administration; administered every other day; for 14 days) inhibits primary tumor growth in the E0771 breast cancer model of C57BL/6 mice^[2].
Ranitidine (dose enabling mice to ingest 6-8 mg/kg per day; added to drinking water; changed every 3 days; treatment starting from weaning (~4 weeks) until the end of the experiment (23-26 weeks)) increases the latency of breast tumorigenesis and reduces the number of tumors in LKB1^-/-NIC mice^[2].